Stoke Therapeutics files for at-the-market offering of up to $200 million in stock
STOK•At-the-market offering filing
Stoke Therapeutics filed a prospectus supplement for an at-the-market offering of up to $200 million of common stock.
Shares may be sold from time to time under its controlled equity sales agreement with Cantor Fitzgerald.
The offering uses the company’s Form S-3 automatic shelf registration statement filed March 18, 2026.
